Abbott Tests Ace the Test of Time

In a need-for-speed medical world, Abbott's diagnostics rise up to the challenge, helping deliver better patient outcomes.

ABBOTT

Abbott is No. 10 on the DiversityInc Top 50 Companies List 


Suppose for a moment you're a doctor. Or a nurse. Or any healthcare professional.

In your world, you're seeing more patients than ever and more of them are older. New diseases are emerging and mutating. You're under more pressure to keep costs down. And time is of the essence – your patient would really just like to know what's wrong. Now. You'd like to know, too.

Feeling the pressure?

Today, diagnostic testing influences up to 70 percent of health care decisions worldwide. People expect and sometimes need fast, accurate test results so their doctors can assign a proper diagnosis and get their patients on the fastest route to recovery.

Abbott's all over that idea. With about 1.5 billion people estimated to reach 65 or older by 2050, and chronic diseases projected to account for between half and three-fourths of the disease burden by 2030, Abbott's diagnostics business will be innovating to help people live longer, healthier lives for many years to come.

Since 1972, Abbott has driven innovation across medical diagnostics, pioneering new technologies and solutions that transform the way patients and healthcare providers receive accurate and timely results for diseases such as cancers, infectious disease, cardiovascular and more. Today, it's an industry leader in the large $50 billion global diagnostics market.

About 4 billion tests are conducted each year using Abbott testing platforms; its platforms screen 60 percent of the world's blood supply and the business holds No. 1 positions in point-of-care testing (U.S.) and blood screening (U.S. and globally). In all, Abbott's diagnostics business achieved $4.8 billion in sales in 2016 and is known as a consistent driver of results for the company with mid-to-high single digit sales growth the past several years.

The secret lies in not just bringing a test to a customer – but solutions to their challenges. That means having the right menu of high quality tests, scalability for labs of all sizes, and the informatics tools that help labs operate more efficiently while elevating the role that diagnostics plays in helping patients.

Recently, Abbott began rolling out a family of diagnostic instruments designed to help simplify diagnostic testing while delivering results that drive better patient outcomes.

The name of the family, Alinity, is derived from a combination of "alignment," "innovation" and "unity." The harmonized family of next-generation diagnostic systems covers key areas of testing and positions Abbott to change the industry's testing paradigm and expedite patient care worldwide. It offers improved automation, throughput, space efficiency, speed of diagnosis and ease of use. These new platforms maximize the testing output within a smaller footprint – an important feature for labs that process tens of thousands of patient samples, but are often short on space.

All this, combined with the company's innovative informatics tools?

You might say it helps take the pressure off.

Abbott: Connected Devices Turn Data Into Better Health

Abbott's Robert Ford Joins a Panel Discussing the Potential for Connected Medical Devices to Improve Patient Care and Drive Better Outcomes.

Originally Published by Abbott.

Today's medical devices are creating terabytes of information that gives patients, doctors and health providers real-time insight into someone's vital statistics, heart health and even bloodwork.

But can all this new information really make someone healthier?

Read More Show Less

Abbott Introduces the Afinion™ 2 Analyzer Rapid Test System for Diabetes Management

State-of-the-art multi-assay test system helps people with diabetes get the HbA1c results they need within three minutes — allowing more time for consultation and care during a single healthcare visit.

Originally Published by Abbott.

Abbott announced the launch of its Afinion™ 2 analyzer in the U.S., the newest generation of the Afinion test system. The Afinion 2 builds on Abbott's heritage in diabetes care by empowering patients with information about their health that they can discuss with their providers during a single visit.

Read More Show Less

Abbott's Xience Sierra Heart Stent Receives National Reimbursement in Japan to Treat People with Coronary Artery Disease

Coronary artery disease is the most common form of heart disease, which is the second leading cause of death in Japan.

Originally Published by Abbott.

Abbott announced that Japan's Ministry of Health Labour and Welfare (MHLW) granted national reimbursement for XIENCE Sierra™, the newest generation of the company's gold-standard XIENCE everolimus-eluting coronary stent. XIENCE Sierra improves upon previous versions of XIENCE with an enhanced stent design, a new delivery system, and unique sizes to help doctors treat challenging cases.

XIENCE Sierra was designed to help doctors more easily treat people with difficult-to-treat blockages that involve multiple or totally blocked arteries or complications such as diabetes. Complex cases are increasingly prevalent as people with coronary artery disease are living longer.

"Extensive clinical data and 10 years of real-world experience with the XIENCE family of stents provide doctors with confidence that they are treating their patients with one of the safest stents available," said Chuck Brynelsen, senior vice president of Abbott's vascular business. "National reimbursement of XIENCE Sierra will provide people in Japan with greater access to this life-changing technology that can help them live their best lives."

Coronary artery disease is the most common form of heart disease, which is the second leading cause of death in Japan. National reimbursement in Japan will enable doctors to treat more patients with XIENCE Sierra through the country's health insurance plans. XIENCE Sierra was approved in Japan on April 4, 2018, received CE Mark in Europe late last year, and is under review with the U.S. Food and Drug Administration.

XIENCE has been studied in over 100 clinical trials and in 10 years of global real-world experience. Its safety profile is unprecedented with consistent low rates of stent thrombosis, even in complex cases. More than eight million people worldwide have received a XIENCE stent since its initial regulatory approval.